KNBIF (Kane Biotech) Change In Other Working Capital: $-0.13 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Kane Biotech Change In Other Working Capital?

Kane Biotech KNBIF -10.00% Change In Other Working Capital is $-0.13 Mil as of Jun. 2026. The stock has 5 warning signs investors should review.

Kane Biotech's Change In Other Working Capital for the quarter that ended in Jun. 2026 was $0.00 Mil. It means Kane Biotech's Other Working Capital stayed the same from Mar. 2026 to Jun. 2026 .

Kane Biotech's Change In Other Working Capital for the fiscal year that ended in Dec. 2025 was $-0.17 Mil. It means Kane Biotech's Other Working Capital declined by $0.17 Mil from Dec. 2024 to Dec. 2025 .

Kane Biotech Change In Other Working Capital Historical Data

* Premium members only.

The historical data trend for Kane Biotech's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kane Biotech Change In Other Working Capital Chart

Kane Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Other Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.40 -0.04 -1.13 -1.62 -0.17

Kane Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -0.12 -0.00 0.00

Kane Biotech Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Change In Other Working Capital of $-0.13 Mil mean?
Kane Biotech (KNBIF) has a Change In Other Working Capital of $-0.13 Mil as of Jun. 2026. Change In Other Working Capital is any increase or decrease between periods of other working capital. View historical data on Kane Biotech and its competitors.
Is Kane Biotech's Change In Other Working Capital too high?
Kane Biotech's current Change In Other Working Capital is $-0.13 Mil.
How does Kane Biotech's Change In Other Working Capital compare to VRTX and REGN?
Kane Biotech's Change In Other Working Capital of $-0.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Other Working Capital for a Biotechnology company?
A good Change In Other Working Capital depends on the Biotechnology industry context. However, Change In Other Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Other Working Capital mean?
A high Change In Other Working Capital can signal that a stock is expensive relative to its fundamentals. Change In Other Working Capital is any increase or decrease between periods of other working capital. View historical data on Kane Biotech and its competitors. Kane Biotech's current Change In Other Working Capital is $-0.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current Change In Other Working Capital of $-0.13 Mil. The current Change In Other Working Capital is $-0.13 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Other Working Capital calculated?
Change In Other Working Capital is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current Change In Other Working Capital is $-0.13 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kane Biotech Business Description

Other Exchanges KNE:Canada
Address 290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.